G vs NOVT: Which Stock Is the Better Buy?
Genpact Limited and Novanta Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Technology.
AI verdict — G vs NOVT, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Genpact Limited (G) | Novanta Inc. (NOVT) | |
|---|---|---|
| Market cap | $5.4B | $5.5B |
| Revenue (latest FY) | $5.08B | $980.60M |
| Net income (latest FY) | $552.49M | $53.83M |
| Revenue growth (5y CAGR) | 6.5% | 10.7% |
| Net margin | 10.9% | 5.5% |
| Return on equity | 21.7% | 4.1% |
| P/E ratio | 9.9 | 110.8 |
| Dividend yield | 2.3% | — |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full G vs NOVT breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open G's full financials → Open NOVT's full financials →More comparisons
Frequently asked questions
Which is bigger, G or NOVT?
Novanta Inc. is larger by market capitalization — $5.5B versus $5.4B.
Which grows faster, G or NOVT?
Over the last five fiscal years, Novanta Inc. grew revenue faster — 10.7%/yr versus 6.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.